Laura Senovilla
Papers
1
Total Citations
129
H-Index
1
About
Dr. Laura Senovilla is a leading figure in cancer immunology, best known for her groundbreaking work on immunogenic cell death (ICD) and oncolytic peptides. Her research centers on understanding how specific therapeutic agents can transform dying cancer cells into potent vaccines that activate the immune system. Her most cited work, "The oncolytic peptide LTX-315 triggers immunogenic cell death" (2016, 129 citations), demonstrates that this cationic amphilytic peptide selectively permeabilizes mitochondrial membranes, inducing a unique form of caspase-independent necrosis. Crucially, Dr. Senovilla showed that intratumoral injection of LTX-315 not only kills cancer cells but also stimulates a robust T lymphocyte-mediated anticancer immune response, effectively turning the tumor into its own vaccine. This dual mechanism—direct cytotoxicity coupled with immune activation—represents a paradigm shift in cancer therapy. Her contributions have been instrumental in advancing the concept of ICD as a cornerstone of modern immuno-oncology, with her work on LTX-315 paving the way for clinical trials exploring oncolytic peptides as a strategy to overcome resistance to conventional therapies and checkpoint inhibitors.
Research Focus
Key Achievements
Top Papers
- 1The oncolytic peptide LTX-315 triggers immunogenic cell death129 citations · 2016